Asset
RUSFERTIDE
PROTAGONIST THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05210790 | phase3 | active_not_recruiting | 2022-04-01 | 2025-02-21 | Protagonist Therapeutics, Inc. | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera |
| NCT04057040 | phase2 | completed | 2019-10-01 | 2023-02-14 | Protagonist Therapeutics, Inc. | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) |
| NCT04767802 | phase2 | completed | 2021-02-02 | 2023-03-15 | Protagonist Therapeutics, Inc. | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit |
| NCT04202965 | phase2 | completed | 2020-03-19 | 2021-10-06 | Protagonist Therapeutics, Inc. | PTG-300 in Subjects With Hereditary Hemochromatosis |
| NCT04516382 | phase1 | completed | 2020-09-14 | 2021-01-12 | Protagonist Therapeutics, Inc. | Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.